KURA ONCOLOGY INC. overview

NEW YORK, NY / ACCESSWIRE / May 15, 2017 / Kura Oncology, Inc. (NASDAQ: KURA ) will be discussing their earnings results in their Q1 Earnings Call to be held May 15, 2017 at 4:30 PM Eastern Time. To listen to the event live – visit https://www.investornetwork.com/company/24621 . Replay Information The replay will be available online at https://www.investornetwork.com/company/24621 . About Investor Network Investor Network (IN) is a new financial content community, serving millions of unique...

LA JOLLA, Calif., Jan. 17, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company, today announced that the first patient has been dosed in its Phase 2 clinical trial of tipifarnib in patients with chronic myelomonocytic leukemia (CMML). “Objective responses, including complete responses, have been previously observed with tipifarnib in CMML. Our goals with this Phase 2 study are to confirm the level of activity of tipifarnib in this patient...

LA JOLLA, Calif., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical stage biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) accepted the company’s Investigational New Drug (IND) application to begin Phase 1 clinical testing of KO-947, its small molecule inhibitor of extracellular-signal-regulated kinases 1 and 2 (ERK1/2) as a treatment for cancers in which the mitogen activated protein kinase (MAPK) pathway is...

LA JOLLA, Calif., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company, today announced the appointment of Steven H. Stein, M.D., to its board of directors. Dr. Stein currently serves as Executive Vice President and Chief Medical Officer of Incyte Corporation. “We are thrilled to have Steven join our board during this pivotal time at Kura,” said Troy Wilson, Ph.D., J.D., President and Chief Executive Officer of Kura Oncology....

LA JOLLA, Calif., Dec. 01, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company, today presented preclinical data highlighting the identification and characterization of KO-947, its development candidate targeting ERK1/2 kinases. The company has also presented preclinical data relating to the identification and optimization of potent and selective inhibitors of the menin-MLL interaction. Both presentations took place at the EORTC-NCI-AACR...

LA JOLLA, Calif., Nov. 15, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq:KURA), a clinical stage biopharmaceutical company developing precision medicines for cancer, today announced it will be presenting two posters at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (ENA 2016), taking place November 29 – December 2, 2016 in Munich. The presentations will feature preclinical data from Kura Oncology’s KO‒947 ERK inhibitor and menin-MLL inhibitor programs....

LA JOLLA, Calif., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Kura Oncology, Inc., (Nasdaq:KURA) a clinical stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today reported third quarter 2016 financial results and recent business highlights. “During the third quarter, we have continued to advance our tipifarnib development program,” said Troy Wilson, Ph.D., J.D., President and CEO of Kura Oncology. “Our Phase 2 HRAS solid tumor...